Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Palbociclib Prevents CDK4/6 Dependent-Myeloproliferation and Myelofibrosis

Helene Duparc, Delphine Muller, Ileana Antony-Debre, PhD PharmD, Caroline Marty, PhD, Najet Debili, Jean-Luc Villeval, PhD, Isabelle Plo, William Vainchenker, Laure Gilles, PhD, Hana Raslova

Blood (2020) 136 (Supplement 1): 25.

https://doi.org/10.1182/blood-2020-141092

Published: 2020

Journal Articles

In Vitro and In Vivo Interactions between Stromal and Leukemic Cells

Amina Aouida, Florian Beghi, Jean-Luc Villeval, PhD, Valérie Edmond, PhD, William Vainchenker, Monika Wittner, PhD, Fawzia Louache, PhD, Houda Haouas, PhD

Blood (2020) 136 (Supplement 1): 35.

https://doi.org/10.1182/blood-2020-136268

Published: 2020

Journal Articles

Disease Phenotype and Clonal Amplification in Calreticulin del52 and ins5 Knock-in Mice Are Dependent on the Type of Mutations and Gene Dosage

Camélia Benlabiod, Maira da Costa Cacemiro, PhD, Thomas Balligand, MD, Barbara Panneau-Schmaltz, PhD, Delphine Muller, Laure Touchard, Patrick Gonin, DVM, Jean-Luc Villeval, PhD, Stefan N Constantinescu, MD PhD, Hana Raslova, PhD, William Vainchenker, MD PhD, Isabelle Plo, Caroline Marty, PhD

Blood (2019) 134 (Supplement_1): 311.

https://doi.org/10.1182/blood-2019-127918

Published: 2019

Journal Articles

Differential Impact of Interferon Alpha on JAK2 V617F and Calr Mutated Hematopoietic Stem and Progenitor Cells in Classical MPN

Matthieu Mosca, PhDstudent, Lamia Lamrani, PhD, Christophe Marzac, MD, Amandine Tisserand, Valérie Edmond, PhD, Tracy Dagher, PhDstudent, Mira El-Khoury, PhD, Caroline Marty, PhD, Hugo Campario, PharmD, Nicole Casadevall, MD, Eric Solary, MD PhD, Hana Raslova, PhD, Bruno Cassinat, PharmD, PhD, Stefan N Constantinescu, MD, Jean-Jacques Kiladjian, MD PhD, Francois Girodon, MD PhD, Jean-Luc Villeval, PhD, William Vainchenker, MD PhD, Isabelle Plo, PhD

Blood (2018) 132 (Supplement 1): 4333.

https://doi.org/10.1182/blood-2018-99-114744

Published: 2018

Journal Articles

Specific and Synergistic Targeting of JAK2V617F Cells By Interferon Alpha and Arsenic

Nabih Maslah1, PharmD, Tracy Dagher, PhDstudent, Valérie Edmond, PhD, Bruno Cassinat, PharmD, PhD, Valérie Lallemand-Breitenbach, PhD, Emmanuelle Verger, PhD, Isabelle Plo, PhD, Jean-Jacques Kiladjian, MD PhD, Jean-Luc Villeval, PhD, Hugues de Thé, MD PhD

Blood (2018) 132 (Supplement 1): 52.

https://doi.org/10.1182/blood-2018-99-112518

Published: 2018

Journal Articles

HSP27: A Therapeutic Target in Myelofibrosis

Margaux Sevin, Nicolas Pernet, Franck Vitte, MD, Selim Ramla, Paul Sagot, MD PhD, Laurent Martin, MD PhD, Jean Luc Villeval, PhD, Catherine Lacout, Isabelle Plo, PhD, Carmen Garrido, PhD, Francois Girodon, MD PhD, Aurelie de Thonel, PhD

Blood (2016) 128 (22): 1963.

https://doi.org/10.1182/blood.V128.22.1963.1963

Published: 2016

Journal Articles

Complete Inhibition of STAT5 Phosphorylation Is Achieved By Combination of JAK1/2 and PI3K/mTOR Inhibitors in in Vitro and In Vivo MPN Models

Niccolò Bartalucci, PhD, Laura Calabresi, BiSci, Serena Martinelli, BiSci, Manjola Balliu, PhD, Jean-Luc Villeval, PhD, Francesco Annunziato, PhD, Alessandro M. Vannucchi

Blood (2015) 126 (23): 2824.

https://doi.org/10.1182/blood.V126.23.2824.2824

Published: 2015

Journal Articles

Thrombopoietin Activates STAT2 Inducing Type I Interferon Effects and Gene Expression: Implications for in Vivo Tpo Treatment and for Myeloproliferative Neoplasms

Stefan N Constantinescu, MD PhD Prof., Jean-Philippe Defour, BPharm,, Celine Mouton, Isabelle Plo, William Vainchenker, MD PhD, Jean-Luc Villeval, PhD, Thomas Michiels, MD PhD, Judith Staerk, Christian Pecquet, PhD

Blood (2014) 124 (21): 820.

https://doi.org/10.1182/blood.V124.21.820.820

Published: 2014

Journal Articles

Consequences of the Presence of the JAK2V617F Mutation in Endothelial Cells: Towards a Better Understanding of the Increased Angiogenesis in Myeloproliferative Neoplasms

Badr Kilani, Juliana Vieira Dias, PhD, Virginie Gourdou-Latyszenok, Eric Lippert, PhD, Raj Sewduth, Cécile Duplaa, PhD, Jean-Luc Villeval, PhD, Thierry Couffinhal, MD PhD, Chloe James, MD PhD

Blood (2014) 124 (21): 102.

https://doi.org/10.1182/blood.V124.21.102.102

Published: 2014

Journal Articles

Calr Mutants Retroviral Mouse Models Lead to a Myeloproliferative Neoplasm Mimicking an Essential Thrombocythemia Progressing to a Myelofibrosis

Caroline Marty, PhD, Nivarthi Harini, Christian Pecquet, PhD, Ilyas Chachoua, Vitalina Gryshkova, PhD, Jean-Luc Villeval, PhD, Stefan N. Constantinescu, MD PhD, Robert Kralovics, PhD, William Vainchenker, MD, PhD, Isabelle Plo

Blood (2014) 124 (21): 157.

https://doi.org/10.1182/blood.V124.21.157.157

Published: 2014

Journal Articles

The PI3K Specific Inhibitor BKM120 Results Effective and Synergizes With Ruxolitinib In Preclinical Models Of Myeloproliferative Neoplasms

Niccolò Bartalucci, PhD, Costanza Bogani, PhD, Serena Martinelli, BiSci, Carmela Mannarelli, BiSci, Jean-Luc Villeval, PhD, Alessandro M. Vannucchi, MD

Blood (2013) 122 (21): 1599.

https://doi.org/10.1182/blood.V122.21.1599.1599

Published: 2013

Journal Articles

Effect Of The JAK1/2 Inhibitor GS-0387 (momelotinib) On The Anemia Associated With a Preclinical Murine Model Of Human Primary Myelofibrosis

Jean-Luc Villeval, PhD, Claudine Moratal, M2, Franck Debeurme, Catherine Lacout, Eric Solary, MD, PhD, William Vainchenker, MD, PhD, Christopher J Burns, PhD, Gregg Smith, PhD

Blood (2013) 122 (21): 2851.

https://doi.org/10.1182/blood.V122.21.2851.2851

Published: 2013

Journal Articles

Use Of 46/1 Haplotype Permits To Follow JAK2 V617F Clonal Architecture In PV Patients: Clonal Evolution and Impact Of IFNα Treatment

Salma Hasan, PhD student, Bruno Cassinat, PharmD, PhD, Jean-Pierre Le Couédic, Fabrizia Favale, Barbara Monte-Mor, Catherine Lacout, Eric Solary, MD, PhD, Jean-Luc Villeval, PhD, Nicole Casadevall, MD, Jean-Jacques Kiladjian, MD, PhD, William Vainchenker, MD, PhD, Isabelle Plo, Ph.D

Blood (2013) 122 (21): 4109.

https://doi.org/10.1182/blood.V122.21.4109.4109

Published: 2013

Journal Articles

Combined Inhibition of JAK2 and mTOR Signaling Results in Enhanced Efficacy in in-Vitro and Preclinical Mouse Models of JAK2V617F-Driven Myeloproliferative Disease

Alessandro M. Vannucchi, MD, Niccolò Bartalucci, PhD, Costanza Bogani, PhD, Serena Martinelli, BiSci, Lorenzo Tozzi, PhD, Alberto Bosi, MD, Jean-Luc Villeval, PhD

Blood (2012) 120 (21): 708.

https://doi.org/10.1182/blood.V120.21.708.708

Published: 2012

Journal Articles

Combination Treatment with JAK2 and PI3K Inhibitors in Myeloproliferative Neoplasms

Meng Ling Choong, PhD, Christian Pecquet, PhD, Shi Jing Tai, Jacklyn WY Yong, PhD, Vishal Pendharkar, SiFang Wang, Jean-Philippe Defour, BPharm, Carmen C. Diaconu, PhD, Kanda Sangthongpitag, PhD, Jean-Luc Villeval, PhD, William Vainchenker, MD, PhD, Stefan N. Constantinescu, MD, PhD, May Ann Lee, PhD

Blood (2012) 120 (21): 180.

https://doi.org/10.1182/blood.V120.21.180.180

Published: 2012

Journal Articles

46/1 Haplotype Permits to Follow JAK2 Homologous Recombination: Modeling JAK2 V617F clonal Architecture in PV Patients

Salma Hasan, PhD Student, Jean Pierre Le Couedic, Fabrizia Favale, Barbara Monte-Mor, Catherine Lacout, Nicole Casadevall, MD, Eric Solary, Jean-Luc Villeval, PhD, Isabelle Plo, Ph.D, William Vainchenker, MD, PhD

Blood (2012) 120 (21): 1757.

https://doi.org/10.1182/blood.V120.21.1757.1757

Published: 2012

Journal Articles

The Cell Cycle Regulator CDC25A Is a Target for JAK2 V617F Oncogene

Emilie-Fleur Gautier, Christian Recher, MD, PHD, Camille Laurent, MD, Caroline Marty, PhD, Jean-Luc Villeval, PhD, Cécile Demur, MD, Francois Delhommeau, PharmD, PhD, Elizabeth Hexner, MD, Stephane Giraudier, MD, PhD, Nicolas Bonnevialle, MD, Bernard Ducommun, MD, PhD, Guy Laurent, MD PHD, Stéphane Manenti, PhD, Véronique Mansat- De Mas, PharmD, PhD

Blood (2011) 118 (21): 1385.

https://doi.org/10.1182/blood.V118.21.1385.1385

Published: 2011

Journal Articles

JAK2 V617F Promotes Stem Cell Amplification Driving MPN Clonal Dominance in Mice and Treatment by IFNa Prevents This Effect

Caroline Marty, PhD, Catherine Lacout, Marie Cuingnet, MD, Salma Hasan, Eric Solary, MD, PhD, William Vainchenker, MD, PhD, Jean-Luc Villeval, PhD

Blood (2011) 118 (21): 616.

https://doi.org/10.1182/blood.V118.21.616.616

Published: 2011

Journal Articles

Platelet Phenotype and Thrombosis In JAK2 V617F Mice

Lamia Lamrani, Catherine Lacout, Veronique Ollivier, Benoit HO Tin Hoe, William Vainchenker, MD, PhD, Jean-Luc Villeval, PhD, Martine Jandrot-Perrus

Blood (2011) 118 (21): 618.

https://doi.org/10.1182/blood.V118.21.618.618

Published: 2011

Journal Articles

Increased Myelofibrosis in Thrombospondin-1-Null Mice Is Associated with Enhanced TGF-β1-Mediated Response by Bone Marrow Fibroblasts

Solène Evrard, Micheline Tulliez, MD, Eva Zetterberg, MD, PhD, Jan Palmblad, MD, PhD, William Vainchenker, MD, PhD, Jean-Luc Villeval, PhD, Stéphane Giraudier, MD, PhD, Orianne Wagner-Ballon, MD, PhD

Blood (2008) 112 (11): 2796.

https://doi.org/10.1182/blood.V112.11.2796.2796

Published: 2008

NARROW

Palbociclib Prevents CDK4/6 Dependent-Myeloproliferation and Myelofibrosis

In Vitro and In Vivo Interactions between Stromal and Leukemic Cells

Disease Phenotype and Clonal Amplification in Calreticulin del52 and ins5 Knock-in Mice Are Dependent on the Type of Mutations and Gene Dosage

Differential Impact of Interferon Alpha on JAK2 V617F and Calr Mutated Hematopoietic Stem and Progenitor Cells in Classical MPN

Specific and Synergistic Targeting of JAK2V617F Cells By Interferon Alpha and Arsenic

HSP27: A Therapeutic Target in Myelofibrosis

Complete Inhibition of STAT5 Phosphorylation Is Achieved By Combination of JAK1/2 and PI3K/mTOR Inhibitors in in Vitro and In Vivo MPN Models

Thrombopoietin Activates STAT2 Inducing Type I Interferon Effects and Gene Expression: Implications for in Vivo Tpo Treatment and for Myeloproliferative Neoplasms

Consequences of the Presence of the JAK2V617F Mutation in Endothelial Cells: Towards a Better Understanding of the Increased Angiogenesis in Myeloproliferative Neoplasms

Calr Mutants Retroviral Mouse Models Lead to a Myeloproliferative Neoplasm Mimicking an Essential Thrombocythemia Progressing to a Myelofibrosis

The PI3K Specific Inhibitor BKM120 Results Effective and Synergizes With Ruxolitinib In Preclinical Models Of Myeloproliferative Neoplasms

Effect Of The JAK1/2 Inhibitor GS-0387 (momelotinib) On The Anemia Associated With a Preclinical Murine Model Of Human Primary Myelofibrosis

Use Of 46/1 Haplotype Permits To Follow JAK2 V617F Clonal Architecture In PV Patients: Clonal Evolution and Impact Of IFNα Treatment

Combined Inhibition of JAK2 and mTOR Signaling Results in Enhanced Efficacy in in-Vitro and Preclinical Mouse Models of JAK2V617F-Driven Myeloproliferative Disease

Combination Treatment with JAK2 and PI3K Inhibitors in Myeloproliferative Neoplasms

46/1 Haplotype Permits to Follow JAK2 Homologous Recombination: Modeling JAK2 V617F clonal Architecture in PV Patients

The Cell Cycle Regulator CDC25A Is a Target for JAK2 V617F Oncogene

JAK2 V617F Promotes Stem Cell Amplification Driving MPN Clonal Dominance in Mice and Treatment by IFNa Prevents This Effect

Platelet Phenotype and Thrombosis In JAK2 V617F Mice

Increased Myelofibrosis in Thrombospondin-1-Null Mice Is Associated with Enhanced TGF-β1-Mediated Response by Bone Marrow Fibroblasts

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only